• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Melinda Magyari Addresses the Use of Disease-Modifying MS Therapies in Children

Video

Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, addresses the current state of knowledge on using disease-modifying therapies to treat children with multiple sclerosis (MS).

Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, addresses the current state of knowledge on using disease-modifying therapies to treat children with multiple sclerosis (MS).

Transcript

What is the current understanding about how to use disease-modifying therapies in children and adolescents with MS?

We don’t know a lot about it. This was my question looking at my own registry. I haven't really seen many similar studies published from other countries to see whether those not-existing guidelines has been interpreted the same way as we did in Denmark. So it would, I would encourage everybody having a cohort registry to publish these data.

Related Videos
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Marla Black Morgan, MD, Phoebe Neurology Associates
Elizabeth Grush, MBA
Raj Chovatiya, MD, PhD, MSCI.
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Erin Weber, MS
Lynae Darbes, PhD
Kenny Cole, MD
Richard Lafayette, MD, FACP, Stanford University Medical Center
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.